Clinical characteristics.

Fucosidosis is characterized by developmental delay, intellectual disability, psychomotor regression and cognitive decline, coarse facial features, recurrent respiratory infections, and musculoskeletal manifestations (kyphoscoliosis, joint contractures). Radiographs show variable features of dysostosis multiplex. Dermatologic manifestations include telangiectases and angiokeratoma. Ophthalmologic and cardiac manifestations and hypergonadotropic hypogonadism are common. Seizures, hepatosplenomegaly, hearing loss, and hernias are also reported. Phenotype is variable and has been categorized as more severe (type I) and less severe (type II). Individuals with type I fucosidosis typically die prior to age ten years due to respiratory infections and neurologic deterioration; those with type II fucosidosis can live into adulthood.

Diagnosis/testing.

The diagnosis of fucosidosis is established in a proband with biallelic pathogenic variants in FUCA1 identified by molecular genetic testing or reduced alpha-L-fucosidase enzyme activity in leukocytes.

Management.

Targeted therapy: Hematopoietic stem cell transplantation (HSCT) is considered if the diagnosis is established early before central nervous system deterioration. To date, very few individuals with fucosidosis have undergone HSCT.

Supportive care: Developmental and educational support; treatment of spasticity per orthopedist / physical medicine and rehabilitation specialist; physical therapy and occupational therapy including stretching; hypersalivation management; analgesia and palliative care support for pain; management of recurrent infections and poor respiratory clearance per pulmonologist; feeding therapy and gastrostomy tube as needed for poor weight gain; specialty management for orthopedic, ocular, cardiac, and endocrine manifestations; standard treatment of seizures per neurologist; hearing aids as needed; surgical management of umbilical hernia as needed; transitional care plans; family and social work support.

Surveillance: Annual developmental assessment, neurology evaluation, and behavioral assessment; physical medicine and occupational and physical therapy assessment of mobility and self-help skills; assessment of pain, respiratory status, feeding, nutrition, and growth every six to 12 months; assessment by orthopedist for contractures and scoliosis as needed; ophthalmology evaluation annually or as needed; clinical cardiology assessment with electrocardiogram and echocardiogram every six to 12 months; assessment for hypogonadotropic hypogonadism including growth evaluation in childhood, puberty, and at adulthood; audiology evaluation annually; assessment of family needs at each visit.

Evaluation of relatives at risk: Clarify the genetic status of apparently asymptomatic older and younger at-risk sibs of an affected individual in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.

Genetic counseling.

Fucosidosis is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for a FUCA1 pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the FUCA1 pathogenic variants have been identified in an affected family member, molecular genetic carrier testing for at-risk relatives and prenatal/preimplantation genetic testing are possible.

Suggestive Findings

Fucosidosis should be suspected in probands with the following clinical, laboratory, and imaging findings and family history.

Clinical findings

• Developmental delay / intellectual disability with regression
• Postnatal short stature
• Coarse facial features: a rounded, heavy appearance with prominent brows, a wide nose with a flat nasal bridge, thick vermilion of the upper and lower lips, prognathism, and macroglossia
• Recurrent respiratory infections
• Kyphosis, scoliosis, gibbus deformity
• Skin findings (telangiectases, angiokeratoma)
• Ophthalmologic findings (dilated and tortuous retinal and conjunctival vessels, microaneurysms of conjunctival vessels, corneal opacities)
• Seizures
• Feeding difficulties, including swallowing problems
• Other neurologic features (flexion contractures, spasticity, loss of ambulation)
• Cardiac manifestations (mitral valve regurgitation, cardiomyopathy)
• Hypergonadotropic hypogonadism
• Hepatomegaly/splenomegaly

Laboratory findings. Increased urine oligosaccharides [Puente-Ruiz et al 2023]

Imaging findings

• Radiographs show dysostosis multiplex (short odontoid processes, cervical platyspondyly, thoracolumbar vertebrae with anterior tonguing, wedge-shaped lumbar vertebrae, wide ribs, flared iliac bones, and bullet-shaped bones in the hands and feet) in 58% of individuals [Willems et al 1991].
• Kyphosis and/or scoliosis
• Delayed skeletal maturation, deformed or absent carpal bones [Lee et al 1977]
• On brain imaging, prominent white matter abnormalities of the globus pallidus are a specific finding of fucosidosis, helping to distinguish it from other neurometabolic disorders [Zubarioglu et al 2015]. Progressive cerebral atrophy is seen with significant signal changes in the thalamus [Panmontha et al 2016].

Family history is consistent with autosomal recessive inheritance (e.g., affected sibs and/or parental consanguinity). Absence of a known family history does not preclude the diagnosis.

Establishing the Diagnosis

Clinical Description

Fucosidosis is characterized by multisystemic manifestations including facial dysmorphism, cardiac, respiratory, and skeletal complications, and progressive psychomotor decline. Although there is a phenotypic spectrum, individuals with fucosidosis have been categorized as type I (more severe and rapidly progressive) and type II (milder and slowly progressive). To date, approximately 200 individuals have been identified with biallelic pathogenic variants in FUCA1 [Stenson et al 2020].

Onset. Individuals with type I fucosidosis typically have onset of clinical manifestations before age one year. In those with type II fucosidosis, onset occurs in childhood or adolescence.

Developmental delay with regression. Following a period of normal development in infancy, up to 95% of affected individuals have progressive neurocognitive deterioration and up to 87% have motor deterioration [Willems et al 1991]. Psychomotor decline of motor, language, and cognitive skills was noted in 60% of individuals at a median age of 18 ± 4.5 months [Ben Turkia et al 2008]. Forty-one percent of individuals lost the ability to sit, 38% lost the ability to stand, 50% became unable to walk alone, and 67% lost the ability to speak. Twenty-eight percent of individuals had a rapid neurologic deterioration with complete loss of the ability to walk, stand, sit, or talk before age five years. Slower neurologic deterioration and maintenance of the ability to sit, stand, walk, or talk after age ten years was documented in 53% of individuals. In the remaining 19%, the course of neurologic deterioration was intermediate.

Behavioral problems such as aggressiveness or frustration may occur with psychosocial decline. In one adolescent, repeated episodes of psychosis were signs of disease progression and responded to anti-psychotic therapy [Puente-Ruiz et al 2023].

Progressive neurologic degeneration can result in hypersalivation and feeding difficulties requiring tube feeding. Flexion contractures of legs and arms can develop [Snodgrass 1976], contributing to pain. Spastic quadriparesis with increased deep tendon reflexes has been described [Malatt et al 2015, Zubarioglu et al 2015, Shaukat et al 2016] and is estimated to affect up to 40% of all individuals with fucosidosis [Wali et al 2019]. Gradually increasing spasticity with bilateral increased deep tendon reflexes and unsustained ankle clonus may result in unsteady gait, associated with excessive femoral anteversion, tibial torsion, mild metatarsus adductus, and in-toeing [Terespolsky et al 1996]. Mild-to-moderate spasticity is reported in individuals with type II fucosidosis, and some individuals maintain mobility.

Intellectual disability. Individuals with type I fucosidosis have more severe learning disability as compared to those with type II fucosidosis.

Short stature becomes evident postnatally. The height of 91% of individuals was reported to be below the fifth centile [Willems et al 1991], while the weight of 77% of individuals was below the fifth centile. Adults with type II fucosidosis have short stature of the fifth to sixth centile [Puente-Ruiz et al 2023].

Coarse facial features are common, including prominent brows, fullness of the eyelids with ptosis, wide nose with flat nasal bridge, long philtrum, thick vermilion of the upper and lower lips, macroglossia, gingival hypertrophy, and prognathism [Snodgrass 1976, Oner et al 2007, Sánchez et al 2016, Jiang et al 2017]. Some individuals do not develop coarse facial features [Shaukat et al 2016].

Recurrent infections. Up to 78% of individuals experience recurrent respiratory tract infections [Willems et al 1991]. Intermittent otitis media, upper respiratory tract infections, and breathing difficulties during sleep as a result of partial upper airway obstruction have been documented [Terespolsky et al 1996]. Moreover, a recurrent respiratory infection every one or two months despite normal immunologic tests [Wang et al 2020] and diffuse emphysema with small areas of atelectasis have been reported [Durand et al 1969]. Recurrent respiratory infections are less common in those with type II fucosidosis in the second and third decade of life [Puente-Ruiz et al 2023]. One individual age 14 years with type I fucosidosis developed a Streptococcus intermedius frontal brain abscess; investigations of neutrophil oxidative burst, humoral, and innate immune systems were normal [R Wang, unpublished data].

Musculoskeletal manifestations. Nonspecific features of dysostosis multiplex may affect up to 58% of individuals [Willems et al 1991]; however, the skeletal manifestations are less severe than those seen in individuals with mucopolysaccharidoses and more similar to skeletal findings of alpha-mannosidosis. Spine radiographs show small thoracolumbar vertebrae with anterior tonguing, short odontoid pegs, cervical platyspondyly, and broad ribs. Features suggestive of inflammation have also been reported, including joint swelling, synovitis, and antinuclear antibody positivity [Wynne et al 2018]. Rib deformities, scoliosis with partial fusion of lower thoracic vertebrae, and gibbous deformity of lumbar vertebrae have been described, as well as absent scaphoid, trapezium, and trapezoid bones in the wrists [Snodgrass 1976]. Joint contractures are also a common feature [Cragg et al 1997].

Telangiectases/angiokeratoma. Dermatologic abnormalities were documented in 60% of individuals and included telangiectases on the skin or conjunctivae and angiokeratoma [Willems et al 1991]. Some individuals have only telangiectases without angiokeratoma [Wang et al 2020]. The number of angiokeratomas increases with age but can be highly variable. Red-purple pinhead-sized raised skin lesions usually develop on the lower abdomen and genitalia, while tiny scattered angiomas cover most of the body [Puente-Ruiz et al 2023]. Angiokeratoma corporis diffusum was present in most individuals (51%), particularly in those living to age ten years and older. Angiokeratomas within the papillary dermis are proliferative ectatic blood vessels limited by a flattened endothelium containing erythrocytes [Kanitakis et al 2005].

Ophthalmologic involvement is reported in individuals with type I and II fucosidosis. Blepharospasm is common. Dilated and tortuous retinal veins were observed in 54%; dilated and tortuous conjunctival vessels in 53%. Bulbar and, to a lesser extent, palpebral conjunctivae have dilated tortuous vessels, some with saccular dilatations [Snodgrass 1976]. Microaneurysms of conjunctival vessels were reported in 41%, corneal opacities in 11%, pigmentary retinopathy in 7%, and vision loss in 6% of individuals [Willems et al 1991, Stepien et al 2020]. Severe visual impairment is uncommon.

It was shown that storage material accumulates in conjunctival, retinal, and skin vessels. Histologic assessment of the conjunctiva endothelial cells has shown two distinct types of vacuoles – clear ones with a reticular structure similar to those seen in the mucopolysaccharidoses and dark inclusions with a dense granular material [Libert et al 1976, Libert 1984].

The anterior chambers are of normal depth with clear cornea and lenses. The fundi show macular changes similar to bull's-eye retinopathy; the foveal area has fine brown pigmentation ringed by a zone of hypopigmentation. The rest of the macula has fine brownish and/or slate blue pigmentary lesion with occasional clumps of dark brown discoloration. No undue tortuosity of macular vessels are present; the discs and vessels are normal.

Cardiac findings. Mild mitral regurgitation was found in 50% of individuals investigated [Ben Turkia et al 2008], but cardiomyopathy is not common [Ip et al 2002, Wang et al 2020]. An enlarged heart with left ventricular hypertrophy and dilatation of right cavity can be observed on echocardiogram and the electrocardiogram may show incomplete right bundle branch block [Durand et al 1969]. Cloudy degeneration of myocardium and stasis in coronary vessels was also previously observed [Durand et al 1969]. Individuals with type II fucosidosis can have milder cardiac manifestations or absence of cardiac disease.

Endocrine abnormalities may be observed in the third decade of life in individuals with type II fucosidosis including hypergonadotropic hypogonadism [McCarron & Stepien 2025].

Seizures were documented in up to 38% of all reported individuals with fucosidosis [Wali et al 2019]. Seizure types vary; generalized epilepsy has been reported [Terespolsky et al 1996]. Seizures occur less frequently or are milder in those with type II fucosidosis.

Organomegaly. Hepatomegaly was reported in 21/53 (40%) individuals with fucosidosis [Willems et al 1991], and was most often mild and not progressive. Liver enzymes were only mildly elevated in 25% and elevated enzyme concentrations were irrespective of the presence of hepatomegaly. The presence of splenomegaly was reported in 25%. If present, splenomegaly was mild and not progressive.

Hearing impairment. Hearing is usually intact [Snodgrass 1976]. There are, however, individuals with impaired hearing [Sánchez et al 2016], asymmetric mild-to-moderate sensorineural hearing loss, and eustachian tube dysfunction [Malatt et al 2015]. Mild sensorineural hearing loss can be seen in adults with type II fucosidosis [Puente-Ruiz et al 2023].

Umbilical hernia was reported in 9% of individuals [Willems et al 1991, Puente-Ruiz et al 2023].

Neuroimaging. There is evidence of hypomyelination, with extensive, confluent, progressive, and symmetric signal anomaly in the periventricular and subcortical white matter [Terespolsky et al 1996, Galluzzi et al 2001, Oner et al 2007, Jain et al 2012, Ediz et al 2016]. Marked hypointensity on T₂/FLAIR sequences and hyperintensity on T₁ sequences are seen bilaterally in the globus pallidus, which is unique to fucosidosis [Inui et al 2000, Oner et al 2007, Jain et al 2012, Ediz et al 2016]. A hypointense area on T₂-weighted imaging in the bilateral globus pallidus may indicate the presence of high levels of iron in echo-gradient MRI [Zubarioglu et al 2015], and, in combination with curvilinear T₂-hyperintense areas within lentiform nuclei, creates a sign sometimes called "eye of the tiger" [Wang et al 2020].

Cerebellar volume was noted to be increased in early stages of fucosidosis [Kau et al 2011]. Generalized cerebral and cerebellar atrophy was observed with disease progression [Galluzzi et al 2001, Oner et al 2007, Malatt et al 2015, Ediz et al 2016, Jiang et al 2017] and was more commonly documented in individuals with type II fucosidosis [Galluzzi et al 2001]. Among those who survived beyond age 30 years, brain CT abnormalities included infra- and supratentorial volume loss, in particular in the frontal lobes [Ikeda et al 1984]. Ventricular dilatation and focal areas of hypodensity were also observed [Kessler et al 1981]. The prominent white matter abnormalities and low signal of the globus pallidus may help distinguish it from other neurometabolic disorders [Galluzzi et al 2001, Saleh-Gohari et al 2018].

Brain MR spectroscopy typically shows a decreased N-acetylaspartate (NAA)-to-choline ratio, a characteristic abnormal peak at 3.8 ppm [Oner et al 2007, Ediz et al 2016], and a double peak at 1.2 ppm [Kaur et al 2019]. The NAA:creatinine ratio was decreased with an unusual lactic acid peak at 1.33 ppm in the bilateral basal ganglia and posterior limb of internal capsule [Jiang et al 2017].

Prognosis. Death before age ten years occurs in less than half of individuals (43%) [Willems et al 1991]. Approximately 60% of individuals die secondary to respiratory infections and neurologic deterioration [Ben Turkia et al 2008]. Life expectancy is limited and varies respective of the fucosidosis type (I or II).

• Individuals with early-onset clinical manifestations tend to show faster neurologic deterioration leading to mortality at a young age [Willems et al 1991]. In those with type I fucosidosis, death typically occurs prior to age ten years.
• Individuals with type II fucosidosis can live into adulthood, typically up to the third decade [Puente-Ruiz et al 2023].

Genotype-Phenotype Correlations

Given the rarity of the condition and limited information about pathogenic variants, no clinically relevant genotype-phenotype correlations have been identified.

Prevalence

Fucosidosis is a rare disease with a very low incidence of <1:200,000 [Gowda et al 2020]. To date, approximately 120 individuals with fucosidosis have been reported in the literature [Willems et al 1991, Lin et al 2007, Wang et al 2020]. The highest reported incidences are in Italy, the Hispanic American population of New Mexico and Colorado, and Cuba [Willems et al 1991, Malatt et al 2015].

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with fucosidosis, the evaluations summarized in Table 4 (if not performed as part of the evaluation that led to the diagnosis) are recommended.

Treatment of Manifestations

Surveillance

To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations in Table 6 are recommended.

Evaluation of Relatives at Risk

It is appropriate to clarify the genetic status of apparently asymptomatic older and younger at-risk sibs of an affected individual in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures. Evaluations can include:

• Molecular genetic testing if the FUCA1 pathogenic variants in the family are known;
• Alpha-L-fucosidase enzyme activity testing if the pathogenic variants in the family are not known. (Note: Confirmation of the diagnosis through evaluation of clinical findings and molecular genetic testing is recommended.)

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Therapies Under Investigation

Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

Mode of Inheritance

Fucosidosis is inherited in an autosomal recessive manner.

Risk to Family Members

Parents of a proband

• The parents of an affected child are presumed to be heterozygous for a FUCA1 pathogenic variant.
• If a molecular diagnosis has been established in the proband, molecular genetic testing is recommended for the parents of the proband to confirm that both parents are heterozygous for a FUCA1 pathogenic variant and to allow reliable recurrence risk assessment.
• If a pathogenic variant is detected in only one parent and parental identity testing has confirmed biological maternity and paternity, it is possible that one of the pathogenic variants identified in the proband occurred as a de novo event in the proband or as a postzygotic de novo event in a mosaic parent [Jónsson et al 2017]. If the proband appears to have homozygous pathogenic variants (i.e., the same two pathogenic variants), additional possibilities to consider include:
  • A single- or multiexon deletion in the proband that was not detected by sequence analysis and that resulted in the artifactual appearance of homozygosity;
  • Uniparental isodisomy for the parental chromosome with the pathogenic variant that resulted in homozygosity for the pathogenic variant in the proband.
• Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.

Sibs of a proband

• If both parents are known to be heterozygous for a FUCA1 pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
• Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.

Offspring of a proband. Due to the severity of the disorder, individuals with fucosidosis do not typically reproduce.

Other family members. Each sib of the proband's parents is at a 50% risk of being a carrier of a FUCA1 pathogenic variant.

Carrier Detection

Molecular genetic carrier testing for at-risk relatives requires prior identification of the FUCA1 pathogenic variants in the family.

Related Genetic Counseling Issues

See Management, Evaluation of Relatives at Risk for information on evaluating at-risk sibs for the purpose of early diagnosis and treatment.

Family planning

• The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or are at risk of being carriers.

DNA banking. Because it is likely that testing methodology and our understanding of genes, pathogenic mechanisms, and diseases will improve in the future, consideration should be given to banking DNA from probands in whom a molecular diagnosis has not been confirmed (i.e., the causative pathogenic mechanism is unknown). For more information, see Huang et al [2022].

Prenatal Testing and Preimplantation Genetic Testing

Once the FUCA1 pathogenic variants have been identified in an affected family member, prenatal and preimplantation genetic testing are possible.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal and preimplantation genetic testing. While most health care professionals would consider use of prenatal and preimplantation genetic testing to be a personal decision, discussion of these issues may be helpful.

Molecular Pathogenesis

FUCA1 encodes the enzyme alpha-L-fucosidase, which functions in the lysosomes of the cell and removes fucose sugars from the sugar chains that are attached (glycosylated) to proteins. An impairment in the ability to remove fucose from oligosaccharides results in a buildup of fucose-containing oligosaccharides in body tissues and fluids. While the exact mechanisms of how oligosaccharide storage proceeds to disease pathology are not entirely clear, the accumulation of lysosomal fucosyl-oligosaccharides results in cellular dysfunction notably in the central nervous system, resulting in the prominent neurocognitive/neurologic manifestations of fucosidosis. Oligosaccharide accumulation elsewhere in the body gives rise to the somatic (facial, musculoskeletal, etc.) manifestations of the disease.

Mechanism of disease causation. Loss of function

Author Notes

The authors are actively involved in clinical research regarding individuals with fucosidosis. They would be happy to communicate with persons who have any questions regarding diagnosis of fucosidosis or other considerations.

Acknowledgments

The authors would like to acknowledge the ISMRD and MPS Society advocacy groups for the support they offer patients and their families.

Revision History

• 2 April 2026 (sw) Review posted live
• 12 November 2025 (ks) Original submission

Literature Cited

• Ben Turkia H, Tebib N, Azzouz H, Abdelmoula MS, Bouguila J, Sanhaji H, Miladi N, Maire I, Caillaud C, Kaabachi N, Ben Dridi MF. Phenotypic spectrum of fucosidosis in Tunisia. J Inherit Metab Dis. 2008;31 Suppl 2:S313-6. [PubMed: 18651239]
• Beratis NG, Varvarigou-Frimas A, Beratis S, Sklower SL. Angiokeratoma corporis diffusum in GM1 gangliosidosis, type 1. Clin Genet. 1989;36:59-64. [PubMed: 2504516]
• Cragg H, Williamson M, Young E, O'Brien J, Alhadeff J, Fang-Kircher S, Paschke E, Winchester B. Fucosidosis: genetic and biochemical analysis of eight cases. J Med Genet. 1997;34:105–10. [PMC free article: PMC1050861] [PubMed: 9039984]
• Durand P, Borrone C, Della Cella G. Fucosidosis. J Pediatr. 1969;75:665–74. [PubMed: 4241464]
• Ediz SS, Aralasmak A, Yilmaz TF, Toprak H, Yesil G, Alkan A. MRI and MRS findings in fucosidosis; a rare lysosomal storage disease. Brain Dev. 2016;38:435-8. [PubMed: 26515723]
• Galluzzi P, Rufa A, Balestri P, Cerase A, Federico A. MR brain imaging of fucosidosis type I. AJNR Am J Neuroradiol. 2001;22:777-80. [PMC free article: PMC7976004] [PubMed: 11290499]
• Gowda VK, Srinivasan VM, Vegda H, Bhat M. Fucosidosis with pathogenic variant in FUCA1 gene. Indian J Pediatr. 2020;87:867-8. [PubMed: 32125660]
• Huang SJ, Amendola LM, Sternen DL. Variation among DNA banking consent forms: points for clinicians to bank on. J Community Genet. 2022;13:389-97. [PMC free article: PMC9314484] [PubMed: 35834113]
• Ikeda S, Kondo K, Oguchi K, Yanagisawa N, Horigome R, Murata F. Adult fucosidosis: histochemical and ultrastructural studies of rectal mucosa biopsy. Neurology. 1984;34:451-6. [PubMed: 6538300]
• Inui K, Akagi M, Nishigaki T, Muramatsu T, Tsukamoto H, Okada S. A case of chronic infantile type of fucosidosis: clinical and magnetic resonance image findings. Brain Dev. 2000;22:47-9. [PubMed: 10761834]
• Ip P, Goh W, Chan KW, Cheung PT. A novel FUCA1 mutation causing fucosidosis in a Chinese boy. J Inherit Metab Dis. 2002;25:415-6. [PubMed: 12408193]
• Jain P, Ramesh K, Mohamed A, Kumar A, Gulati S. Teaching NeuroImages: distinct neuroimaging features of fucosidosis. Neurology. 2012;78:e33. [PubMed: 22291069]
• Jiang M, Liu S, Jiang H, Lin Y, Shao Y, Hu H, Zhao X, Liu H, Huang Y, Liu L, et al. Brain abnormalities in fucosidosis: transplantation or supportive therapy? Metab Brain Dis. 2017;32:317–20. [PubMed: 28238202]
• Jónsson H, Sulem P, Kehr B, Kristmundsdottir S, Zink F, Hjartarson E, Hardarson MT, Hjorleifsson KE, Eggertsson HP, Gudjonsson SA, Ward LD, Arnadottir GA, Helgason EA, Helgason H, Gylfason A, Jonasdottir A, Jonasdottir A, Rafnar T, Frigge M, Stacey SN, Th Magnusson O, Thorsteinsdottir U, Masson G, Kong A, Halldorsson BV, Helgason A, Gudbjartsson DF, Stefansson K. Parental influence on human germline de novo mutations in 1,548 trios from Iceland. Nature. 2017;549:519-22. [PubMed: 28959963]
• Kanitakis J, Allombert C, Doebelin B, Deroo-Berger MC, Grande S, Blanc S, Claudy A. Fucosidosis with angiokeratoma. Immunohistochemical and electromicroscopic study of a new case and literature review. J Cutan Pathol. 2005;32:506–11. [PubMed: 16008696]
• Kau T, Karlo C, Gungor T, Prietsch V, Kellenberger CJ, Scheer I, Boltshauser E. Increased cerebellar volume in the early stage of fucosidosis: a case control study. Neuroradiology. 2011;53:509-16. [PubMed: 21384124]
• Kaur A, Dhaliwal AS, Raynes H, Naidich TP, Kaufman DM. Diagnosis and supportive management of fucosidosis: a case report. Cureus. 2019;11:e6139. [PMC free article: PMC6907717] [PubMed: 31886074]
• Kessler RM, Altman DH, Martin-Jimenez R. Cranial CT in fucosidosis. AJNR Am J Neuroradiol. 1981;2:591-2. [PMC free article: PMC8335255] [PubMed: 6797284]
• Lee FA, Donnell GN, Gwinn JL. Radiographic features of fucosidosis. Pediatr Radiol. 1977;5:204-8. [PubMed: 122443]
• Libert J. [Fucosidosis. Ocular ultrastructure]. J Fr Ophtalmol. 1984;7:519–27. [PubMed: 6520331]
• Libert J, Van Hoof F, Tondeur M. Fucosidosis: ultrastructural study of conjunctiva and skin and enzyme analysis of tears. Invest Ophthalmol. 1976;15:626–39. [PubMed: 955828]
• Lin SP, Chang JH, de la Cadena MP, Chang TF, Lee-Chen GJ. Mutation identification and characterization of a Taiwanese patient with fucosidosis. J Hum Genet. 2007;52:553-6. [PubMed: 17427030]
• Malatt C, Koning JL, Naheedy J. Skeletal and brain abnormalities in fucosidosis, a rare lysosomal storage disorder. J Radiol Case Rep. 2015;9:30-8. [PMC free article: PMC4638372] [PubMed: 26622931]
• McCarron E, Stepien K. Hormonal dysfunction as a long-term complication of Glycoproteinoses. 2025. Abstract. Minneapolis, MN: ISMRD International Glycoproteinoses Forum; 2025.
• Miano M, Lanino E, Gatti R, Morreale G, Fondelli P, Celle ME, Stroppiano M, Crescenzi F, Dini G. Four year follow-up of a case of fucosidosis treated with unrelated donor bone marrow transplantation. Bone Marrow Transplant. 2001;27:747-51. [PubMed: 11360116]
• Oner AY, Cansu A, Akpek S, Serdaroglu A. Fucosidosis: MRI and MRS findings. Pediatr Radiol. 2007;37:1050–52. [PubMed: 17704911]
• Panmontha W, Amarinthnukrowh P, Damrongphol P, Desudchit T, Suphapeetiporn K, Shotelersuk V. Novel mutations in the FUCA1 gene that cause fucosidosis. Genet Mol Res. 2016;15. [PubMed: 27706744]
• Puente-Ruiz N, Ellis I, Bregu M, Chen C, Church HJ, Tylee KL, Gladston S, Hackett R, Oldham A, Virk S, Hendriksz C, Morris AAM, Jones SA, Stepien KM. Long-term outcomes in two adult siblings with fucosidosis - diagnostic odyssey and clinical manifestations. Mol Genet Metab Rep. 2023;37:101009. [PMC free article: PMC10694746] [PubMed: 38053939]
• Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-24. [PMC free article: PMC4544753] [PubMed: 25741868]
• Saleh-Gohari N, Saeidi K, Zeighaminejad R. A novel homozygous frameshift mutation in the FUCA1 gene causes both severe and mild fucosidosis. J Clin Pathol. 2018;71:821-4. [PubMed: 29588375]
• Sánchez LR, Oatts JT, Duncan JL, Packman S, Moore AT. Ocular findings in a patient with fucosidosis. Am J Ophthalmol Case Rep. 2016;4:83–86. [PMC free article: PMC5757485] [PubMed: 29503934]
• Shaukat R, Raza SM, Yuns ZM, Omar A, Afroze B. α-fucosidosis- two brothers presenting with dysostosis multiplex. Egypt J Med Hum Genet. 2016;17:243–46.
• Snodgrass MB. Ocular findings in a case of fucosidosis. Br J Ophthalmol. 1976;60:508–11. [PMC free article: PMC1017540] [PubMed: 952824]
• Stenson PD, Mort M, Ball EV, Chapman M, Evans K, Azevedo L, Hayden M, Heywood S, Millar DS, Phillips AD, Cooper DN. The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting. Hum Genet. 2020;139:1197-207. [PMC free article: PMC7497289] [PubMed: 32596782]
• Stepien KM, Ciara E, Jezela-Stanek A. Fucosidosis-clinical manifestation, long-term outcomes, and genetic profile-review and case series. Genes (Basel). 2020;11:1383. [PMC free article: PMC7700486] [PubMed: 33266441]
• Terespolsky D, Clarke JT, Blaser SI. Evolution of the neuroimaging changes in fucosidosis type II. J Inherit Metab Dis. 1996;19:775–81. [PubMed: 8982951]
• Wali G, Wali GM, Sue CM, Kumar KR. A novel homozygous mutation in the FUCA1 gene highlighting fucosidosis as a cause of dystonia: case report and literature review. Neuropediatrics. 2019;50:248–52. [PubMed: 31064022]
• Wang L, Yang M, Hong S, Tang T, Zhuang J, Huang H. Fucosidosis in a Chinese boy: a case report and literature review. J Int Med Res. 2020;48:300060520911269. [PMC free article: PMC7132800] [PubMed: 32238081]
• Willems PJ, Gatti R, Darby JK, Romeo G, Durand P, Dumon JE, O'Brien JS. Fucosidosis revisited: a review of 77 patients. Am J Med Genet. 1991;38:111–31. [PubMed: 2012122]
• Wynne E, Wynne K, Cleary M, Brogan PA. Fucosidosis mimicking juvenile idiopathic arthritis. Rheumatol Adv Pract. 2018;2:rky040. [PMC free article: PMC6649943] [PubMed: 31431977]
• Vellodi A, Cragg H, Winchester B, Young E, Young J, Downie CJ, Hoare RD, Stocks R, Banerjee GK. Allogeneic bone marrow transplantation for fucosidosis. Bone Marrow Transplant. 1995;15:153-8. [PubMed: 7742750]
• Zubarioglu T, Kiykim E, Zeybek CA, Cansever MS, Benbir G, Aydin A, Yalcinkaya C. Clinical and neuroradiological approach to fucosidosis in a child with atypical presentation. Ann Indian Acad Neurol. 2015;18:471-74. [PMC free article: PMC4683895] [PubMed: 26713028]